BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Apr 8, 2020
Deals

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

...in 2021. Cytovia will be responsible for one arm of the therapy, which will target NCR1...
...of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets NCR1 (NKP46; CD335) - Natural cytotoxicity triggering receptor 1...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

...binding CD16 and a bispecific Fv domain targeting tumor antigens and the NK cell-activating receptor NCR1...
...for biosimilar versions of rituximab. TARGET/MARKER/PATHWAY: Fc γ receptor III (CD16; FCGR3); natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335...
...Aix-Marseille University, Marseille, France email: vivier@ciml.univ-mrs.fr Sandi Wong Aix-Marseille University AstraZeneca plc Innate Pharma S.A. Sanofi Fc gamma receptor III (CD16) (FCGR3) Natural cytotoxicity triggering receptor 1 (NCR1) (NKP46) (CD335) Lymphoma...
BioCentury | Jun 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Cell culture and mouse studies suggest adoptive transfer of IL-15-cultured T cells could help treat B7-H6 tumor cell ligand-positive cancers. CD8 + T cells derived from human donor blood and cultured for...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...CT101-IL2 Fusion protein NKG2D Preclin Innate Pharma S.A. (Euronext:IPH) IPH61 Bispecific antibody Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Candida; fungal infection Cell culture studies identified a glucan-based NKp30 activator that could help treat Cryptococcus neoformans and Candida albicans infections. In vitro , a C. neoformans and C. albicans cell wall glucan bound NKp30...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest activating or overexpressing NCR2 could help treat melanoma. In a human melanoma cell line, supernatant from NK cells activated by the NCR2 ligand PDGFDD decreased growth compared...
BioCentury | Aug 29, 2017
Distillery Therapeutics

Hematology

...with no treatment. Also in the model, inhibition of NK cell activation with antibodies against NCR1...
...inhibit the mechanism by which NK cells damage trophoblasts in FNAIT. TARGET/MARKER/PATHWAY: Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335...
...Heyu Ni, St. Michael’s Hospital, Toronto, Ontario email: nih@smh.ca Chris Lieu Fc gamma receptor IIIa (FCGR3A) (FcgammaRIIIa) (CD16a) Natural cytotoxicity triggering receptor 1 (NCR1) (NKP46) (CD335)...
BioCentury | Aug 11, 2017
Preclinical News

Study links FNAIT miscarriages to NK cells

...Additionally, inhibition of NK cell activation by antibodies against natural cytotoxicity triggering receptor 1 ( NCR1 ; NKP46 ; CD335...
...in autoimmunity (see BioCentury Innovations, Aug. 10) . Chris Lieu University of Toronto Fc gamma receptor III (FCGR3) (CD16) Natural cytotoxicity triggering receptor 1 (NCR1) (NKP46) (CD335)...
Items per page:
1 - 10 of 41